课题基金 / 基金详情

Preclinical Development of Natural Product-Based Agents as Anti-Cancer Drugs

Preclinical Development of Natural Product-Based Agents as Anti-Cancer Drugs
基于天然产物的抗癌药物的临床前开发
批准号:
295575
负责人:
Allingham John S
金额:
$15.05万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-10-01 至 2016-10-01

项目摘要

项目成果

Allingham John S的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cancer metastases (the spreading of cancer cells from one organ or tissue to another) are ultimately the cause of death in 90 percent of cancer patients. Therefore, the need for drugs capable of interfering with this process is enormous. As the actin cyto
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Kinesin motor protein dynamics and mitotic mechanisms in Candida albicans
Development of antibody-drug conjugates that use actin-targeting warheads
CANADA RESEARCH CHAIRHOLDER / TITULAIRE DE CHAIRE DE RECHERCHE DU CANADA
Structural and functional analyses of novel heterodimeric kinesin motors
海外基金